Top

Osteoporosis International

Published in:

01-10-2006 | Original Article

At what hip fracture risk is it cost-effective to treat?

International intervention thresholds for the treatment of osteoporosis

Authors: F. Borgström, O. Johnell, J. A. Kanis, B. Jönsson, C. Rehnberg

Published in: Osteoporosis International | Issue 10/2006

Abstract

Introduction

Intervention thresholds (ITs), the 10-year hip fracture risk at which treatment can be considered to be cost-effective, have previously been estimated for Sweden and the UK.

Objective

The aim of this study was to provide a Markov cohort model platform for a multinational estimation of thresholds at which intervention becomes cost-effective and to investigate and determine the main factors behind differences in these thresholds between countries.

Results and discussion

Intervention thresholds were estimated for Australia, Germany, Japan, Sweden, Spain, the UK and USA using a societal perspective. The model was populated with as much relevant country-specific data as possible. Intervention was assumed to be given for 5 years and to decrease the risk of all osteoporotic fractures by 35%. The societal willingness to pay (WTP) for a quality-adjusted life-year (QALY) gained was set to the gross domestic product (GDP) per capita multiplied by two. In the base case analysis, the 10-year hip fracture probability at which intervention became cost-effective varied across ages and countries. For women starting therapy at an age of 70 years, the IT varied from a hip fracture probability of 5.6% in Japan to 14.7% in Spain. The main factors explaining differences in the IT between countries were the WTP for a QALY gained, fracture-related costs and intervention costs.

Conclusion

The ITs presented in this paper are appropriate for use in treatment guidelines that consider health economic aspects, and they can be used in combination with fracture risk prediction algorithms to improve the selection of patients who are suitable for osteoporotic intervention.

Johannesson M (2001) At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention? Eur Heart J 22:919–925PubMedCrossRef

Kanis JA, Johnell O, Oden A, De Laet C, Oglesby A, Jonsson B (2002) Intervention thresholds for osteoporosis. Bone 31:26–31PubMedCrossRef

Kanis JA, Johnell O, Oden A, Borgstrom F, Johansson H, De Laet C, Jonsson B (2005) Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden. Osteoporos Int 16:6–14PubMedCrossRef

Kanis JA, Borgstrom F, Zethraeus N, Johnell O, Oden A, Jonsson B (2005) Intervention thresholds for osteoporosis in the UK. Bone 36:22–32PubMedCrossRef

Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12:417–427PubMedCrossRef

Kanis JA, Borgstrom F, Johnell O, Oden A, Sykes D, Jonsson B (2005) Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporos Int 16:15–25PubMedCrossRef

Kanis JA, Borgstrom F, Johnell O, Jonsson B (2004) Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. Osteoporos Int 15:862–871PubMedCrossRef

Jonsson L, Borgstrom F, Zethraeus N (2003) Cost-effectiveness of alendronate treatment of osteoporosis in Denmark. An economic evaluation based on the Fracture Intervention Trial. Ugeskr Laeger 165:4112–4116PubMed

Borgstrom F, Zethraeus N (2003) Economic assessment based on a clinical study of risedronate. Fracture prevention in elderly women with osteoporosis is cost-effective. Lakartidningen 100:36–40PubMed

10.

Borgstrom F, Johnell O, Kanis JA, Oden A, Sykes D, Jonsson B (2004) Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics 22:1153–1165PubMedCrossRef

11.

Borgstrom F, Johnell O, Jonsson B, Zethraeus N, Sen SS (2004) Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden. Bone 34:1064–1071PubMedCrossRef

12.

Johnell O, Jonsson B, Jonsson L, Black D (2003) Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 21:305–314PubMedCrossRef

13.

Melton LJ 3rd, Gabriel SE, Crowson CS, Tosteson AN, Johnell O, Kanis JA (2003) Cost-equivalence of different osteoporotic fractures. Osteoporos Int 14:383–388PubMedCrossRef

14.

Borgström F, Kanis JA, Johnell O, Jönsson B (2006) Are costs of fracture proportional to their morbidity?. Osteoporos Int ECCEO abstract 17[Suppl 2]:47

15.

Borgström F, Kanis JA, Johnell O, Jönsson B (2006) Costing fractures for use in health economics modelling. Osteoporos Int ECCEO abstract 17[Suppl 2]: 97

16.

ISPOR (2005) ISPOR pharmacoeconomic guidelines. http://www.ispor.org/PEguidelines/index.asp

17.

Kanis JA, Brazier JE, Stevenson M, Calvert NW, Lloyd Jones M (2002) Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 6:1–146PubMed

18.

Jonsson B, Kanis J, Dawson A, Oden A, Johnell O (1999) Effect and offset of effect of treatments for hip fracture on health outcomes. Osteoporos Int 10:193–199PubMedCrossRef

19.

Jonsson B, Christiansen C, Johnell O, Hedbrandt J (1995) Cost-effectiveness of fracture prevention in established osteoporosis. Osteoporos Int 5:136–142PubMedCrossRef

20.

Stevenson M, Lloyd Jones M, De Nigris E, Brewer N, Davis S, Oakley J (2005) A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 9(22):1–160PubMed

21.

Kanis JA, Johnell O, Oden A, Borgstrom F, Zethraeus N, De Laet C, Jonsson B (2004) The risk and burden of vertebral fractures in Sweden. Osteoporos Int 15:20–26PubMedCrossRef

22.

Eichler HG, Kong SX, Gerth WC, Mavros P, Jonsson B (2004) Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 7:518–528PubMedCrossRef

23.

Commission on Macroeconomics and Health (2001) Report on macroeconomics and health: investing in health for economic development. WHO, Geneva

24.

Murray CJ, Lauer JA, Hutubessy RC, Niessen L, Tomijima N, Rodgers A, Lawes CM, Evans DB (2003) Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet 361:717–725PubMedCrossRef

25.

Murray CJ, Lopez AD (1997) Global mortality, disability, and the contribution of risk factors: global burden of disease study. Lancet 349:1436–1442PubMedCrossRef

26.

Tengs TO, Wallace A (2000) One thousand health-related quality-of-life estimates. Med Care 38:583–637PubMedCrossRef

27.

Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A, De Laet C, Jonsson B (2000) Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 11:669–674PubMedCrossRef

28.

Singer BR, McLauchlan GJ, Robinson CM, Christie J (1998) Epidemiology of fractures in 15,000 adults: the influence of age and gender. J Bone Joint Surg Br 80:243–248PubMedCrossRef

29.

Elffors I, Allander E, Kanis JA, Gullberg B, Johnell O, Dequeker J, Dilsen G, Gennari C, Lopes Vaz AA, Lyritis G et al. (1994) The variable incidence of hip fracture in southern Europe: the MEDOS Study. Osteoporos Int 4:253–263PubMedCrossRef

30.

Euopean Commission – Employment and Social Affairs (1998) Report on Osteoporosis in the European Community - Action for Prevention. European Commission – Employment & Social Affairs, Brussels

31.

Nagata-Kobayashi S, Shimbo T, Fukui T (2002) Cost-effectiveness analysis of screening for osteoporosis in postmenopausal Japanese women. J Bone Miner Metab 20:350–357PubMedCrossRef

32.

Melton LJ 3rd, Crowson CS, O’Fallon WM (1999) Fracture incidence in Olmsted County, Minnesota: comparison of urban with rural rates and changes in urban rates over time. Osteoporos Int 9:29–37PubMedCrossRef

33.

Sanders KM, Seeman E, Ugoni AM, Pasco JA, Martin TJ, Skoric B, Nicholson GC, Kotowicz MA (1999) Age- and gender-specific rate of fractures in Australia: a population-based study. Osteoporos Int 10:240–247PubMedCrossRef

34.

Government Actuary´s Department. Interim Life Tables. http://www.gad.gov.uk/policy_and_stats/life_tables.htm. Access date: 2004-10-15

35.

Instituto Nacional del Estadistica (2002) Tablas de Mortalidad de la Población de España 1998–1999. Madrid

36.

Statistical Yearbook of Sweden (2004). Statistics Sweden, Stockholm

37.

Human Mortality Database. University of California, Berkeley (USA) and Max Planck Institute for Demographic Research (Germany)

38.

Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK (2003) The components of excess mortality after hip fracture. Bone 32:468–473PubMedCrossRef

39.

Oden A, Dawson A, Dere W, Johnell O, Jonsson B, Kanis JA (1998) Lifetime risk of hip fractures is underestimated. Osteoporos Int 8:599–603PubMedCrossRef

40.

Parker MJ, Anand JK (1991) What is the true mortality of hip fractures? Public Health 105:443–446PubMedCrossRef

41.

Borgstrom F, Zethraeus N, Johnell O, Lidgren L, Ponzer S, Svensson O, Abdon P, Ornstein E, Lunsjo K, Thorngren KG, Sernbo I, Rehnberg C, Jonsson B (2005) Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporos Int 1–14

42.

Jonsson B, Christiansen C, Johnell O, Hedbrandt J, Karlsson G (1996) Cost-effectiveness of fracture prevention in established osteoporosis. Scand J Rheumatol Suppl 103:30–38; discussion, pp 39–40PubMedCrossRef

43.

Brecht JG, Kruse HP, Felsenberg D, Mohrke W, Oestreich A, Huppertz E (2003) Pharmacoeconomic analysis of osteoporosis treatment with risedronate. Int J Clin Pharmacol Res 23:93–105PubMed

44.

Hart WM, Rubio-Terres C, Burrell A, Aristegui I, Escobar-Jimenez Y (2002) Análisis farmacoeconómico del tratamiento de la osteoporosis postmenopáusica con risedronato o alendronato. Rev Esp Enferm Metab Óseas 11:97–104

45.

Zethraeus N, Stromberg L, Jonsson B, Svensson O, Ohlen G (1997) The cost of a hip fracture. Estimates for 1,709 patients in Sweden. Acta Orthop Scand 68:13–17PubMedCrossRef

46.

Dolan P, Torgerson DJ (1998) The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporos Int 8:611–617PubMedCrossRef

47.

Kanis JA (2002) Epidemiology and costs of fractures in the UK: background document for male osteoporosis model. Personal communication

48.

Gabriel SE, Tosteson AN, Leibson CL, Crowson CS, Pond GR, Hammond CS, Melton LJ 3rd (2002) Direct medical costs attributable to osteoporotic fractures. Osteoporos Int 13:323–330PubMedCrossRef

49.

OECD Health Data (2005)

50.

Meltzer D (1997) Accounting for future costs in medical cost-effectiveness analysis. J Health Econ 16:33–64PubMedCrossRef

51.

Ekman M, Zethraeus N, Jonsson B (2001) Cost effectiveness of bisoprolol in the treatment of chronic congestive heart failure in Sweden: analysis using data from the Cardiac Insufficiency Bisoprolol Study II trial. Pharmacoeconomics 19:901–916PubMedCrossRef

52.

Meltzer D, Egleston B, Stoffel D, Dasbach E (2000) Effect of future costs on cost-effectiveness of medical interventions among young adults: the example of intensive therapy for type 1 diabetes mellitus. Med Care 38:679–685PubMedCrossRef

53.

Kanis JA, Johnell O, De Laet C, Jonsson B, Oden A, Ogelsby AK (2002) International variations in hip fracture probabilities: implications for risk assessment. J Bone Miner Res 17:1237–1244PubMedCrossRef

54.

Kanis JA, Borgstrom F, De Laet C, Johansson H, Johnell O, Jonsson B, Oden A, Zethraeus N, Pfleger B, Khaltaev N (2005) Assessment of fracture risk. Osteoporos Int 16:581–589PubMedCrossRef

55.

Kanis JA, Johansson H, Johnell O, Oden A, De Laet C, Eisman JA, Pols H, Tenenhouse A (2005) Alcohol intake as a risk factor for fracture. Osteoporos Int 16:737–742PubMedCrossRef

56.

Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, Eisman JA, Fujiwara S, Kroger H, Mellstrom D, Meunier PJ, Melton LJ 3rd, O’Neill T, Pols H, Reeve J, Silman A, Tenenhouse A (2005) Predictive value of BMD for hip and other fractures. J Bone Miner Res 20:1185–1194PubMedCrossRef

57.

Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P, Eisman J, Fujiwara S, Garnero P, Kroger H, McCloskey EV, Mellstrom D, Melton LJ, Pols H, Reeve J, Silman A, Tenenhouse A (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35:375–382PubMedCrossRef

58.

Kanis JA, Johansson H, Oden A, Johnell O, De Laet C, Eisman JA, McCloskey EV, Mellstrom D, Melton LJ 3rd, Pols HA, Reeve J, Silman AJ, Tenenhouse A (2004) A family history of fracture and fracture risk: a meta-analysis. Bone 35:1029–1037PubMedCrossRef

59.

De Laet C, Oden A, Johansson H, Johnell O, Jonsson B, Kanis JA (2005) The impact of the use of multiple risk indicators for fracture on case-finding strategies: a mathematical approach. Osteoporos Int 16:313–318PubMedCrossRef

60.

World Bank (2003) World development indicators. The World Bank, Washington, D.C.

61.

Bacon WE, Maggi S, Looker A, Harris T, Nair CR, Giaconi J, Honkanen R, Ho SC, Peffers KA, Torring O, Gass R, Gonzalez N (1996) International comparison of hip fracture rates in 1988–89. Osteoporos Int 6:69–75PubMedCrossRef

62.

Johnell O, Gullberg B, Allander E, Kanis JA (1992) The apparent incidence of hip fracture in Europe: a study of national register sources. MEDOS Study Group. Osteoporos Int 2:298–302PubMedCrossRef

63.

Zethraeus N, Borgstrom F, Jonsson B, Kanis J (2005) Reassessment of the cost-effectiveness of hormone replacement therapy in Sweden: results based on the Women’s Health Initiative randomized controlled trial. Int J Technol Assess Health Care 21:433–441PubMedCrossRef

64.

Zethraeus N, Johannesson M, Jonsson B (1999) A computer model to analyze the cost-effectiveness of hormone replacement therapy. Int J Technol Assess Health Care 15:352–365PubMed

65.

Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281:2189–2197PubMedCrossRef

66.

Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333PubMedCrossRef

67.

Hillner BE, Hollenberg JP, Pauker SG (1986) Postmenopausal estrogens in prevention of osteoporosis. Benefit virtually without risk if cardiovascular effects are considered. Am J Med 80:1115–1127PubMedCrossRef

68.

Beral V (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:419–427PubMedCrossRef

69.

Bagger YZ, Tanko LB, Alexandersen P, Hansen HB, Mollgaard A, Ravn P, Qvist P, Kanis JA, Christiansen C (2004) Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. Bone 34:728–735PubMedCrossRef

70.

Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441PubMedCrossRef

71.

Randell A, Sambrook PN, Nguyen TV, Lapsley H, Jones G, Kelly PJ, Eisman JA (1995) Direct clinical and welfare costs of osteoporotic fractures in elderly men and women. Osteoporos Int 5:427–432PubMedCrossRef

72.

Report on Government Services 2000 (2000) Canberra, Australia

73.

Stadsledningskontorets redovisningsstab. Stockholms stads budgetavräkning. http://www.stockholm.se Access date: 2004–08–22

74.

Netten A, Rees T, Harrison G; Unit Costs of health and Social Care (2002) Personal Social Services Research Unit, University of Kent

75.

MetLife Mature Market Institute (2003)

Title: At what hip fracture risk is it cost-effective to treat?
International intervention thresholds for the treatment of osteoporosis
Authors: F. Borgström
O. Johnell
J. A. Kanis
B. Jönsson
C. Rehnberg
Publication date: 01-10-2006
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 10/2006
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-006-0107-0

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

At what hip fracture risk is it cost-effective to treat?

International intervention thresholds for the treatment of osteoporosis

Abstract

Introduction

Objective

Results and discussion

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Introduction

Objective

Results and discussion

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2006

Daily nasal spray of hPTH(1–34) for 3 months increases bone mass in osteoporotic subjects: a pilot study

Mortality within 1 year after hip fracture surgical repair in the elderly according to postoperative period: a probabilistic record linkage study in Brazil

Correlation of transmenopausal bone mass in healthy white women: a long-term longitudinal study

The 3D-based scaling index algorithm: a new structure measure to analyze trabecular bone architecture in high-resolution MR images in vivo

Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob rats

Femoral neck cortical geometry measured with magnetic resonance imaging is associated with proximal femur strength